Studying the metabolism of prohibited substances is an essential element in anti-doping research in order to facilitate and improve detectability. Whilst pharmacokinetic studies on healthy volunteers are valuable, they are often difficult, not least due to safety reasons and ethical constraints, especially concerning peptidic substances, which must be administered parenterally. Hence, there is a growing need for suitable in vitro models and sophisticated analytical strategies to investigate the metabolism of protein- and peptide-derived drugs. These include human growth hormone (hGH) and its main mediator insulin-like growth factor-I (IGF-I), both prohibited in professional sports for their anabolic and lipolytic effects, while challenging in their detection, as they occur naturally in the human body.Within this study, the in vitro metabolism of hGH and IGF-I was investigated using a stable-isotope-labelled reporter ion screening strategy (IRIS). A combination of liquid chromatography, high-resolution mass spectrometry, and characteristic immonium ions generated by internal dissociation of the stable-isotope-labelled peptidic metabolites enabled the detection of specific fragments. Several degradation products for hGH and IGF-I were identified within this study. These metabolites, potentially even indicative for subcutaneous administration of the drugs, could serve as promising targets for the detection of hGH and IGF-I misuse in future anti-doping applications.
Altered tryptophan-kynurenine metabolism has been associated with schizophrenia. Beyond healthy-control differences, elevated brain kynurenic acid and reduced peripheral metabolites have been linked to symptoms and cognitive deficits. Nonetheless, exercise has been shown to rebalance this pathway by enhancing peripheral kynurenine turnover, with no clear evidence yet in schizophrenia. This pilot trial from the PsyLetics project investigated whether high-intensity exercise can alter kynurenine metabolism in patients with schizophrenia, and whether improvements in symptoms, psychosocial functioning, and physical health accompany such changes. Ten patients with schizophrenia or schizoaffective disorder and ten matched healthy controls participated. Patients were randomly assigned to either high-intensity training or whole-body vibration training, which served as a control condition. Both interventions lasted eight weeks, three times per week. Pre- and post-intervention assessments included blood analysis of tryptophan metabolites, inflammation, psychiatric interviews, psychosocial functioning scales, physical fitness testing, and body composition. At baseline, patients had lower plasma kynurenine and picolinic acid levels than healthy controls. After the intervention, picolinic acid increased in both training groups, while other metabolites remained unchanged. High-intensity training led to greater improvements in psychosocial functioning and muscular strength than the control condition. Positive symptoms improved in both groups; negative symptoms showed no change. This pilot study suggests that exercise can modulate kynurenine metabolism in schizophrenia, with picolinic acid emerging as a potential marker of clinical improvement. Psychosocial and fitness gains support exercise as a feasible adjunctive intervention, warranting larger studies to clarify underlying mechanisms within the kynurenine pathway.
Advances in analytical techniques have markedly improved the detection of anabolic-androgenic steroids (AAS) in doping controls. This represents a major success for anti-doping efforts, but at the same times raises concerns about inadvertent exposure - not limited to oral ingestion, but also via dermal contact or mucosal absorption. Evaluating the plausibility of such scenarios can be complex, not least because these routes of drug intake can also be deliberately used for doping purposes. Analytical data on transdermal or mucosal absorption and elimination of AAS can be valuable here, particularly regarding the metabolite pattern in urine samples that might help to assess the route of drug delivery. This study investigated the urinary excretion profile of trenbolone and its metabolites after oral, transdermal and buccal administration in healthy male volunteers. Urine samples collected over a period of one week following the administration of 10 mg of trenbolone were analyzed by LC-HRMS, with regard to potential differences in the metabolite profile across the different routes of drug intake. Major trenbolone metabolites were detectable in the urine samples of all participants, however the detection windows varied strongly: Buccal resorption resulted in faster elimination, whereas transdermal application resulted in prolonged detectability, compared to oral administration. A cysteine-conjugated metabolite (M15-cys) was identified that showed higher abundances following transdermal and buccal administration, suggesting its potential as a marker for non-oral intake. In light of the growing importance of transdermal uptake of doping agents, these results provide valuable data for interpreting doping control findings, potentially also relevant for structurally related AAS.
15 July 2026 in Journal of Shoulder and Elbow Surgery
Surgical site infections are a clinically relevant complication in orthopedic surgery, and administration of perioperative antibiotic prophylaxis has been shown to reduce infection rates. This study aimed to identify influencing factors on the concentration of unbound cefazolin in shoulder synovial fluid following the perioperative antibiotic prophylaxis administration of 2 g of cefazolin during shoulder surgery. Patients who underwent arthroscopic or open shoulder surgery within five months were prospectively included. The exclusion criteria were patient age under 18 years, shoulder joint infection, beta-lactam allergy and creatinine clearance below 30 ml/min. All patients received 2 g of cefazolin preoperatively via intravenous short infusion. The infusion duration, sampling time, patient age, body weight, body mass index, American Society of Anesthesiologists (ASA) score, smoking status and diabetes status were documented. Unbound cefazolin concentrations in the synovial fluid were determined using ultrafiltration and ultra-high-performance liquid chromatography coupled to tandem mass spectrometry. Multiple linear regression analysis with backward elimination (significance level p < .05) was used to analyze influencing factors on unbound cefazolin concentration. A total of 62 patients (35 men (56.5%), age 57.1 ± 15.4 years, body weight 88.2 ± 18.5 kg) were included in the final evaluation. The unbound cefazolin concentration was 20.2 ± 8.6 μg/mL. Increasing body weight and current smoking independently negatively influenced the unbound cefazolin concentration (B = -.217, p = < .001 and B = -6.631, p = .002, respectively). No significant correlation was found with age, sex, body mass index, ASA score, diabetic status, creatinine clearance and the time interval between perioperative antibiotic prophylaxis administration and sample collection. Sufficient drug concentrations were detected in all cases against Cutibacterium acnes (2 μg/mL). The fourfold epidemiological cut-off value for Staphylococcus aureus (8 μg/mL) was achieved in 58 patients (93.5%). In 55 patients (88.7%), the unbound drug concentrations were below four times the epidemiological cut-off value for coagulase-negative staphylococci (32 μg/mL). Higher body weight and current smoking are associated with lower unbound cefazolin concentrations in shoulder synovial fluid. Patient-specific adjustment of cefazolin dosing may be considered to optimize perioperative antibiotic prophylaxis.
Purpose: To examine systemic exposure and elution characteristics of liquid vancomycin‐soaked anterior cruciate ligament (ACL) grafts in vivo by assessing serum vancomycin levels over 48 hours after ACL reconstruction and comparing the resulting concentrations with the toxic threshold of 15 to 20 μg/mL. Methods: Patients consenting between October 2023 and January 2024 and undergoing isolated ACL reconstruction or 2‐stage revision after tunnel bone grafting were included. Hamstring or quadriceps grafts were used, with or without meniscal surgery. Six blood samples were taken, first preoperatively and second 10 minutes after tourniquet release and each at 1, 6 to 8, 24, and 48 hours. Soaking time was measured. Vancomycin concentrations were analyzed by tandem mass spectrometry and high‐performance liquid chromatography. Spearman rho correlation coefficients were used to identify relations between the parameters. A P value of <.05 was considered statistically significant. Results: The study included 21 patients (17 men, 4 women, median age: 36, interquartile range [IQR] 16). The highest median levels of vancomycin detectable in peripheral blood were observed both 6 to 8 hours (0.0050 μg/mL, IQR 0.0079 μg/mL) and 24 hours (0.0050 μg/mL, IQR 0.0144 μg/mL) postoperatively. After 48 hours, a median concentration of 0.0021 μg/mL (IQR 0.0032 μg/mL) could still be detected. The maximum serum concentration of vancomycin in all samples was 0.704 μg/mL. Significant correlation was found between the soaking time and measured maximum vancomycin serum concentrations ( r = 0.497; P = .022). Conclusions: Systemic vancomycin concentrations after implantation of a liquid vancomycin‐soaked ACL graft remained well below the established toxic threshold for adverse effects. Additionally, peak systemic concentrations occurred 6 to 24 hours postoperatively, with graft soaking time identified as a factor that significantly influenced systemic levels. Level of Evidence: Level IV, prospective case series.
The use of testosterone‐stimulating peptides for doping purposes is prohibited for male athletes by the World Anti‐Doping Agency (WADA). Among these substances is kisspeptin (KP‐54), its isoforms (KP‐14, KP‐13, and KP‐10), and synthetic receptor agonists such as TAK‐448. Thus, they have been included in the WADA Prohibited List in 2024. To enable effective detection of kisspeptin misuse, reliable analytical methods are required. Consequently, this study aimed to develop liquid chromatography–high‐resolution mass spectrometry‐based (LC‐MS) methods for the detection of kisspeptin and its analogues in human serum and urine. In addition, peptide stability in different biological matrices was investigated, and metabolic stability was characterized in vitro. Extraction methods based on cation‐exchange solid‐phase extraction were optimized, enabling a selective and sensitive LC‐MS analysis with limits of identification (LOI) ranging from 0.8 ng/mL (KP‐54) to 10 pg/mL (TAK‐448). Analysis of a reference population comprising n = 20 serum samples and n = 100 urine samples revealed no detectable signals of endogenous kisspeptins and/or its degradation products. All native kisspeptins investigated showed poor stability in urine and blood; however, several degradation products could be identified. These metabolites could serve as complementary target analytes and improve the detectability of kisspeptins in doping control samples. Overall, the study provides an important foundation for the confirmatory analysis of kisspeptins in doping controls and delivers in vitro insights into their metabolic behavior. Analysis of samples collected after administration of the peptides remains necessary to further assess the detectability and metabolic profiles in authentic samples.